Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system’s ability to recognize and des...

Descripción completa

Detalles Bibliográficos
Autores principales: Oncale, Melody B, Maymani, Hossein, Nastoupil, Loretta J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467338/
https://www.ncbi.nlm.nih.gov/pubmed/31360081
http://dx.doi.org/10.2147/BLCTT.S110665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467338/
https://www.ncbi.nlm.nih.gov/pubmed/31360081
http://dx.doi.org/10.2147/BLCTT.S110665

Ejemplares similares